Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2010 - 2022)

Emergent BioSolutions' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $5.9 million for Q1 2022.

• On a quarterly basis, Non-Current Deffered Revenue fell 88.76% year-over-year to $5.9 million in Q1 2022; TTM through Mar 2022 was $5.9 million, a 88.76% decrease from a year earlier, with the FY2021 full-year figure at $4.7 million, down 91.53% from the prior year.
• Non-Current Deffered Revenue improved to $5.9 million in Q1 2022 per EBS's latest filing, from $4.7 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $85.6 million in Q4 2019 and bottomed at $4.7 million in Q4 2021.
• The 5-year median for Non-Current Deffered Revenue is $62.5 million (2018), against an average of $59.0 million.
• Across the five-year window, Non-Current Deffered Revenue soared 327.49% in 2018 and slumped 91.53% in 2021, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $62.5 million in 2018, then jumped by 36.96% to $85.6 million in 2019, then sank by 35.16% to $55.5 million in 2020, then slumped by 91.53% to $4.7 million in 2021, then grew by 25.53% to $5.9 million in 2022.
• Per Business Quant, the three latest EBS Non-Current Deffered Revenue figures stand at $5.9 million (Q1 2022), $4.7 million (Q4 2021), and $45.3 million (Q3 2021).